KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) EBT Margin (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed EBT Margin for 6 consecutive years, with 304.19% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin rose 363112.0% year-over-year to 304.19%, compared with a TTM value of 863.53% through Dec 2025, down 7360.0%, and an annual FY2025 reading of 863.53%, down 7360.0% over the prior year.
  • EBT Margin was 304.19% for Q4 2025 at Recursion Pharmaceuticals, up from 3135.29% in the prior quarter.
  • Across five years, EBT Margin topped out at 304.19% in Q4 2025 and bottomed at 3935.31% in Q4 2024.
  • Average EBT Margin over 5 years is 1219.62%, with a median of 887.14% recorded in 2023.
  • The sharpest move saw EBT Margin soared 2938181bps in 2021, then plummeted -304413bps in 2024.
  • Year by year, EBT Margin stood at 2564.55% in 2021, then skyrocketed by 83bps to 445.91% in 2022, then crashed by -100bps to 891.18% in 2023, then tumbled by -342bps to 3935.31% in 2024, then surged by 92bps to 304.19% in 2025.
  • Business Quant data shows EBT Margin for RXRX at 304.19% in Q4 2025, 3135.29% in Q3 2025, and 894.23% in Q2 2025.